Rebecca L Galvan, PA
Physician Assistant · Santa Cruz
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Dominican Hospital · Sutter Maternity & Surgery Center of Santa Cruz. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Rebecca L Galvan’s office to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
- Sutter Maternity & Surgery Center of Santa CruzSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 85% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Maternity & Surgery Center of Santa Cruz
Behind the star rating — Deaths: 0 better, 1 the same, 0 worse of 1 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 0 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.04 (0 to 2.12) · 59 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.01 (0.5 to 1.52) | No different | Jul 2022 – Jun 2024 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 63 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 118 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.49) · 116 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.95) · 113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.28 (0.56 to 4) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.41 (0 to 18.05) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.75 (2.52 to 10.98) · 102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.23 to 3.28) · 42 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0 to 1.94) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 30 cases | None | Apr 2023 – Mar 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (9.2 to 14.9) · 3,197 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 506 cases | No different | Jan 2024 – Dec 2024 |
What patients said (203 patients answered, 24% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 5 |
| Overall hospital rating | 5 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 84% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 93% |
| Yes, staff "did" give patients information about help after discharge | 96% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 83% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 87% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 69% |
| "YES", patients would definitely recommend the hospital | 85% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$76,280
Medicare paid this office $76,280 for 426 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 227 | $31,508 | $125 |
| Insertion of lower leg neurostimulator electrode | 53 | $17,953 | $85 |
| Short return visit (20+ min) | 106 | $7,760 | $60 |
| Return visit (30+ min) | 64 | $6,110 | $86 |
| Manual urinalysis test with examination using microscope, automated | 276 | $1,116 | $3 |
See all 9 services
| Long return visit (40+ min) | 227 | $31,508 | $125 |
| Insertion of lower leg neurostimulator electrode | 53 | $17,953 | $85 |
| Short return visit (20+ min) | 106 | $7,760 | $60 |
| Return visit (30+ min) | 64 | $6,110 | $86 |
| Manual urinalysis test with examination using microscope, automated | 276 | $1,116 | $3 |
| Insertion of temporary bladder tube | 20 | $989 | $31 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $860 | $66 |
| Short return visit | 11 | $460 | $38 |
| Ultrasound measurement of bladder capacity after voiding | 35 | $392 | $11 |
Procedures Medicare counted
| Prostate resection | 14 | More than 67% of doctors who do this |
Who their Medicare patients are
426 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 14% · Women 35% · Also on Medicaid 18% · Health risk score 1.22. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 68% · Cancer 35% · Coronary heart disease 24% · Chronic kidney disease 22% · Diabetes 21% · Atrial fibrillation 19% · Depression 16% · Heart failure 13% · COPD 10% · Dementia 5% · Stroke 4%.
The office billed $380,492, Medicare allowed $100,147 and paid $76,280; for 2,193 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 426 | 2,193 | 76 | 1.22 | $380,492 | $76,280 |
| 2023 | 549 | 15,474 | 76 | 1.27 | $560,951 | $119,548 |
| 2022 | 483 | 22,175 | 76 | 1.26 | $524,823 | $118,810 |
| 2021 | 392 | 10,638 | 76 | 1.29 | $338,621 | $78,330 |
| 2020 | 476 | 2,043 | 74 | 1.19 | $298,573 | $67,031 |
| 2019 | 286 | 1,494 | 75 | 1.26 | $158,571 | $34,817 |
| 2018 | 625 | 4,132 | 74 | 1.24 | $398,710 | $88,779 |
| 2017 | 357 | 904 | 75 | 1.33 | $161,247 | $32,937 |
| 2016 | 486 | 1,171 | 74 | 1.24 | $149,288 | $28,052 |
| 2015 | 452 | 1,092 | 74 | 1.26 | $128,674 | $24,268 |
| 2014 | 351 | 769 | 74 | 1.17 | $83,415 | $15,235 |
| 2013 | 283 | 617 | 75 | 1.28 | $66,837 | $14,408 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Insertion of lower leg neurostimulator electrode | 79 | $33,437 | $89 |
| Long return visit (40+ min) | 209 | $27,211 | $124 |
| Injection, testosterone undecanoate, 1 mg | 12 | $18,482 | None |
| Return visit (30+ min) | 120 | $12,920 | $92 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $9,515 | None |
| Short return visit (20+ min) | 71 | $5,148 | $64 |
| Simple change of bladder tube | 22 | $1,895 | $63 |
| Manual urinalysis test with examination using microscope, automated | 357 | $1,390 | $3 |
| Short return visit | 26 | $1,132 | $39 |
| Simple insertion of temporary bladder tube | 16 | $1,017 | $36 |
| Insertion of temporary bladder tube | 21 | $783 | $34 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $542 | $27 |
| Injection of drug or substance under skin or into muscle | 18 | $294 | $10 |
| Ultrasound measurement of bladder capacity after voiding | 20 | $207 | $10 |
2022: 19 services
| Injection, testosterone undecanoate, 1 mg | 17 | $26,418 | None |
| Long return visit (40+ min) | 167 | $24,026 | $133 |
| Insertion of lower leg neurostimulator electrode | 75 | $22,800 | $93 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $7,914 | None |
| Return visit (30+ min) | 61 | $6,518 | $94 |
| Short return visit (20+ min) | 67 | $5,714 | $66 |
| Insertion of temporary bladder tube | 72 | $3,615 | $33 |
| Simple change of bladder tube | 33 | $3,615 | $74 |
| Simple bladder irrigation and/or instillation | 27 | $3,357 | $61 |
| New patient visit (60+ min) | 18 | $2,561 | $142 |
| Simple insertion of temporary bladder tube | 26 | $1,936 | $45 |
| Short return visit | 27 | $1,442 | $40 |
| New patient visit (45+ min) | 12 | $1,394 | $116 |
| Manual urinalysis test with examination using microscope, automated | 291 | $1,347 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $519 | $14 |
| Injection of drug or substance under skin or into muscle | 29 | $492 | $11 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $449 | $24 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $429 | $27 |
| Ultrasound measurement of bladder capacity after voiding | 30 | $292 | $10 |
2021: 17 services
| Insertion of lower leg neurostimulator electrode | 77 | $21,866 | $103 |
| Long return visit (40+ min) | 108 | $14,151 | $122 |
| Injection, testosterone undecanoate, 1 mg | 11 | $11,471 | None |
| New patient visit (60+ min) | 50 | $8,094 | $162 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $3,261 | None |
| Simple bladder irrigation and/or instillation | 17 | $2,874 | $62 |
| Short return visit (20+ min) | 40 | $2,340 | $53 |
| Return visit (30+ min) | 30 | $2,136 | $69 |
| Simple change of bladder tube | 18 | $1,836 | $77 |
| New patient visit (45+ min) | 14 | $1,639 | $117 |
| Insertion of temporary bladder tube | 34 | $1,241 | $32 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 44 | $1,096 | $18 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 30 | $979 | $24 |
| Manual urinalysis test with examination using microscope, automated | 236 | $945 | $3 |
| Simple insertion of temporary bladder tube | 12 | $709 | $51 |
| Injection of drug or substance under skin or into muscle | 21 | $295 | $11 |
| Ultrasound measurement of bladder capacity after voiding | 16 | $167 | $9 |
2020: 8 services
| Long return visit (40+ min) | 329 | $40,679 | $108 |
| Return visit (30+ min) | 64 | $6,398 | $80 |
| Short return visit (20+ min) | 83 | $5,930 | $54 |
| Insertion of temporary bladder tube | 43 | $2,357 | $34 |
| Manual urinalysis test with examination using microscope, automated | 392 | $1,596 | $3 |
| Insertion of lower leg neurostimulator electrode | 14 | $1,368 | $98 |
| Short return visit | 11 | $589 | $35 |
| Ultrasound measurement of bladder capacity after voiding | 26 | $260 | $10 |
2019: 6 services
| Long return visit (40+ min) | 172 | $18,707 | $105 |
| Short return visit (20+ min) | 91 | $6,539 | $55 |
| Return visit (30+ min) | 33 | $2,984 | $81 |
| Insertion of temporary bladder tube | 29 | $1,384 | $34 |
| Manual urinalysis test with examination using microscope, automated | 239 | $1,028 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 13 | $142 | $11 |
2018: 8 services
| Long return visit (40+ min) | 300 | $30,937 | $96 |
| Insertion of lower leg neurostimulator electrode | 79 | $15,000 | $97 |
| Short return visit (20+ min) | 161 | $10,704 | $48 |
| Return visit (30+ min) | 129 | $10,211 | $72 |
| Insertion of temporary bladder tube | 51 | $2,667 | $34 |
| Manual urinalysis test with examination using microscope, automated | 481 | $2,477 | $4 |
| Creation of sling around urethra in female to control leakage | 13 | $1,049 | $81 |
| Ultrasound measurement of bladder capacity after voiding | 24 | $355 | $13 |
2017: 8 services
| Long return visit (40+ min) | 73 | $7,836 | $102 |
| Return visit (30+ min) | 102 | $7,667 | $73 |
| Short return visit (20+ min) | 95 | $4,997 | $43 |
| Insertion of temporary bladder tube | 47 | $1,691 | $30 |
| Manual urinalysis test with examination using microscope, automated | 306 | $1,542 | $4 |
| Bcg (intravesical) per instillation | 11 | $1,334 | None |
| Instillation of anti-cancer drug into bladder | 11 | $826 | $64 |
| Ultrasound measurement of bladder capacity after voiding | 20 | $334 | $16 |
2016: 8 services
| Short return visit (20+ min) | 175 | $11,901 | $47 |
| Insertion of temporary bladder tube | 70 | $4,227 | $38 |
| Return visit (30+ min) | 37 | $2,727 | $74 |
| Manual urinalysis test with examination using microscope, automated | 450 | $2,610 | $4 |
| Complicated insertion of bladder tube | 12 | $1,123 | $80 |
| Creation of sling around urethra in female to control leakage | 12 | $951 | $79 |
| Short return visit | 25 | $748 | $28 |
| Ultrasound measurement of bladder capacity after voiding | 33 | $534 | $15 |
2015: 6 services
| Short return visit (20+ min) | 149 | $10,672 | $49 |
| Manual urinalysis test with examination using microscope, automated | 422 | $2,460 | $4 |
| Insertion of temporary bladder tube | 43 | $2,333 | $38 |
| Return visit (30+ min) | 29 | $2,175 | $72 |
| Short return visit | 36 | $1,461 | $30 |
| Ultrasound measurement of bladder capacity after voiding | 17 | $256 | $14 |
2014: 6 services
| Short return visit (20+ min) | 108 | $6,322 | $45 |
| Insertion of temporary bladder tube | 43 | $2,016 | $37 |
| Manual urinalysis test with examination using microscope, automated | 333 | $1,810 | $4 |
| Short return visit | 46 | $1,614 | $30 |
| Creation of sling around urethra in female to control leakage | 11 | $871 | $79 |
| Return visit (30+ min) | 12 | $821 | $68 |
2013: 4 services
| Short return visit (20+ min) | 94 | $6,874 | $50 |
| Return visit (30+ min) | 26 | $2,199 | $69 |
| Manual urinalysis test with examination using microscope, automated | 258 | $1,504 | $4 |
| Short return visit | 23 | $734 | $29 |
Drugs they prescribed that Part D paid
$36,331
Pharmacies billed $36,331 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 14% of their Part D prescriptions (71 of 504) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
450 generic and 38 brand-name prescriptions · $36,331 in drug cost · 190 antibiotic prescriptions to 138 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 17 | $14,421 | $848 |
| Gemtesa | 11 | $10,612 | $965 |
| Testosterone | 21 | $2,494 | $119 |
| Estradiol | 22 | $1,400 | $64 |
| Methenamine Hippurate | 15 | $1,275 | $85 |
See all 16 drugs
| Myrbetriq | 17 | $14,421 | $848 |
| Gemtesa | 11 | $10,612 | $965 |
| Testosterone | 21 | $2,494 | $119 |
| Estradiol | 22 | $1,400 | $64 |
| Methenamine Hippurate | 15 | $1,275 | $85 |
| Tamsulosin | 58 | $603 | $10 |
| Sulfamethoxazole-Trimethoprim | 46 | $208 | $5 |
| Hydrocodone-Acetaminophen | 46 | $190 | $4 |
| Cephalexin | 42 | $185 | $4 |
| Oxybutynin Chloride Er | 22 | $179 | $8 |
| Nitrofurantoin Mono-Macro | 17 | $164 | $10 |
| Ciprofloxacin | 38 | $110 | $3 |
| Amoxicillin | 18 | $84 | $5 |
| Phenazopyridine | 16 | $77 | $5 |
| Fluconazole | 11 | $60 | $5 |
| Tramadol | 20 | $36 | $2 |
Year by year
| 2024 | 504 | 252 | 14% (71) | 8% | $36,331 |
| 2023 | 565 | 304 | 20% (115) | None | $35,964 |
| 2022 | 387 | 202 | 12% (46) | None | $30,137 |
| 2021 | 331 | 198 | 17% (57) | None | $24,790 |
| 2020 | 636 | 345 | 23% (145) | None | $16,138 |
| 2019 | 270 | 173 | 29% (77) | None | $2,969 |
| 2018 | 591 | 376 | 27% (159) | None | $7,254 |
| 2017 | 369 | 228 | 27% (99) | None | $6,633 |
| 2016 | 741 | 376 | 26% (194) | None | $16,837 |
| 2015 | 687 | 353 | 26% (177) | 11% | $26,360 |
| 2014 | 563 | 269 | 21% (119) | 13% | $24,544 |
| 2013 | 337 | 197 | 24% (82) | 3% | $7,490 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Myrbetriq | 12 | $7,831 | $653 |
| Testosterone | 26 | $5,800 | $223 |
| Methenamine Hippurate | 27 | $2,966 | $110 |
| Tamsulosin | 54 | $790 | $15 |
| Oxybutynin Chloride Er | 15 | $487 | $32 |
| Nitrofurantoin Mono-Macro | 18 | $381 | $21 |
| Cephalexin | 55 | $327 | $6 |
| Hydrocodone-Acetaminophen | 70 | $255 | $4 |
| Sulfamethoxazole-Trimethoprim | 62 | $252 | $4 |
| Ciprofloxacin | 37 | $176 | $5 |
| Amoxicillin | 18 | $88 | $5 |
| Tramadol | 28 | $57 | $2 |
| Levofloxacin | 12 | $51 | $4 |
2022: 12 drugs
| Myrbetriq | 22 | $12,381 | $563 |
| Testosterone | 14 | $4,499 | $321 |
| Methenamine Hippurate | 29 | $3,499 | $121 |
| Estradiol | 17 | $2,190 | $129 |
| Oxybutynin Chloride Er | 24 | $831 | $35 |
| Tamsulosin | 34 | $432 | $13 |
| Cephalexin | 43 | $298 | $7 |
| Sulfamethoxazole-Trimethoprim | 46 | $173 | $4 |
| Ciprofloxacin | 19 | $166 | $9 |
| Hydrocodone-Acetaminophen | 29 | $138 | $5 |
| Amoxicillin | 12 | $61 | $5 |
| Tramadol | 14 | $25 | $2 |
2021: 7 drugs
| Myrbetriq | 21 | $17,444 | $831 |
| Tamsulosin | 57 | $897 | $16 |
| Hydrocodone-Acetaminophen | 51 | $284 | $6 |
| Finasteride | 16 | $218 | $14 |
| Cephalexin | 40 | $183 | $5 |
| Sulfamethoxazole-Trimethoprim | 36 | $110 | $3 |
| Ciprofloxacin | 16 | $63 | $4 |
2020: 12 drugs
| Myrbetriq | 12 | $8,907 | $742 |
| Tamsulosin | 75 | $1,326 | $18 |
| Hydrocodone-Acetaminophen | 131 | $647 | $5 |
| Sulfamethoxazole-Trimethoprim | 147 | $455 | $3 |
| Amoxicillin-Clavulanate Potass | 26 | $304 | $12 |
| Cephalexin | 67 | $278 | $4 |
| Nitrofurantoin Mono-Macro | 15 | $273 | $18 |
| Ciprofloxacin | 35 | $119 | $3 |
| Doxycycline Hyclate | 14 | $113 | $8 |
| Levofloxacin | 13 | $107 | $8 |
| Fluconazole | 18 | $99 | $5 |
| Amoxicillin | 16 | $60 | $4 |
2019: 4 drugs
| Hydrocodone-Acetaminophen | 67 | $326 | $5 |
| Sulfamethoxazole-Trimethoprim | 81 | $272 | $3 |
| Tamsulosin | 18 | $219 | $12 |
| Cephalexin | 33 | $197 | $6 |
2018: 9 drugs
| Hydrocodone-Acetaminophen | 147 | $755 | $5 |
| Cephalexin | 112 | $428 | $4 |
| Sulfamethoxazole-Trimethoprim | 136 | $428 | $3 |
| Tamsulosin | 27 | $419 | $16 |
| Nitrofurantoin Mono-Macro | 19 | $406 | $21 |
| Ciprofloxacin | 30 | $187 | $6 |
| Levofloxacin | 11 | $147 | $13 |
| Amoxicillin | 21 | $111 | $5 |
| Fluconazole | 15 | $52 | $3 |
2017: 5 drugs
| Tamsulosin | 38 | $817 | $21 |
| Hydrocodone-Acetaminophen | 90 | $356 | $4 |
| Cephalexin | 64 | $327 | $5 |
| Sulfamethoxazole-Trimethoprim | 88 | $280 | $3 |
| Amoxicillin | 11 | $54 | $5 |
2016: 9 drugs
| Myrbetriq | 13 | $4,338 | $334 |
| Tamsulosin | 93 | $1,714 | $18 |
| Hydrocodone-Acetaminophen | 178 | $1,496 | $8 |
| Cardura Xl | 11 | $1,295 | $118 |
| Cephalexin | 137 | $660 | $5 |
| Ciprofloxacin | 81 | $457 | $6 |
| Nitrofurantoin Mono-Macro | 13 | $337 | $26 |
| Sulfamethoxazole-Trimethoprim | 90 | $312 | $3 |
| Levofloxacin | 11 | $169 | $15 |
2015: 11 drugs
| Myrbetriq | 24 | $7,952 | $331 |
| Phenazopyridine | 51 | $2,308 | $45 |
| Cardura Xl | 12 | $1,152 | $96 |
| Nitrofurantoin Mono-Macro | 32 | $1,021 | $32 |
| Hydrocodone-Acetaminophen | 158 | $978 | $6 |
| Tamsulosin | 29 | $899 | $31 |
| Ciprofloxacin | 105 | $412 | $4 |
| Cephalexin | 96 | $387 | $4 |
| Sulfamethoxazole-Trimethoprim | 68 | $210 | $3 |
| Levofloxacin | 12 | $151 | $13 |
| Oxycodone-Acetaminophen | 15 | $131 | $9 |
2014: 12 drugs
| Vesicare | 17 | $7,242 | $426 |
| Myrbetriq | 19 | $4,724 | $249 |
| Cialis | 15 | $2,622 | $175 |
| Nitrofurantoin Mono-Macro | 33 | $1,459 | $44 |
| Hydrocodone-Acetaminophen | 104 | $685 | $7 |
| Tamsulosin | 26 | $651 | $25 |
| Phenazopyridine | 38 | $624 | $16 |
| Ciprofloxacin | 95 | $426 | $4 |
| Sulfamethoxazole-Trimethoprim | 66 | $254 | $4 |
| Cephalexin | 58 | $245 | $4 |
| Finasteride | 11 | $152 | $14 |
| Amoxicillin | 13 | $54 | $4 |
2013: 7 drugs
| Nitrofurantoin Mono-Macro | 17 | $525 | $31 |
| Hydrocodone-Acetaminophen | 76 | $498 | $7 |
| Tamsulosin | 14 | $388 | $28 |
| Cephalexin | 44 | $234 | $5 |
| Ciprofloxacin | 55 | $216 | $4 |
| Sulfamethoxazole-Trimethoprim | 45 | $199 | $4 |
| Phenazopyridine | 21 | $157 | $7 |
Money from drug and device companies
$281 in 2024
| 2024 | 3 | 3 | None | $281 |
| 2021 | 1 | 1 | None | $60 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Lithovue | $138 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam System | $72 | 1 payment
|
| Ethicon US | Stratafix | $71 | 1 payment
|
See all 3 published payments
| PROCEPT BioRobotics | Meals · 2024-10-15 | Aquabeam System | $72 |
| Ethicon US | Meals · 2024-08-14 | Stratafix | $71 |
| Boston Scientific | Meals · 2024-05-22 | Lithovue | $138 |
See earlier years (2021)
2021: $60
| Astellas Pharma US | Xtandi | $60 | 1 payment
|
Professional record
- NPI
- 1053560342
- Licence
- CA PA19762
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 2025 Soquel Ave, Santa Cruz, CA, 95062
- NPI first listed
- 2008-09-11
- NPI last updated
- 2013-02-18
This is when the NPI record was last certified, not a medical board exam.